Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

NCT07266493 | Recruiting Phase 2

• 1 other identifier: B2023-222R
• Study Type: interventional
• Target: 26
• Locations: 1 country
• Sites: 1

Brief Summary

This single center, prospective, single arm clinical study aims to evaluate the clinical efficacy and safety of Envafolimab combined with albumin bound paclitaxel and carboplatin as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma.

Conditions

Esophageal Squamous Cell Carcinoma; Neoadjuvant Therapy

Keywords

Esophageal Squamous Cell Carcinoma; Neoadjuvant therapy; Chemotherapy; Immunotherapy

Outcome Measures

Primary Outcomes (1)

• Pathological complete response (pCR) rate

  From enrollment to the end of treatment at 8 weeks

Secondary Outcomes (5)

• R0 resection rate

  From enrollment to the end of treatment at 10 weeks

• Major pathological response rate

  From enrollment to the end of treatment at 8 weeks

• ORR

  From enrollment to the end of Cycle 2 (each cycle is 28 days)

• 3y-RFS rate

  From enrollment until the date of first documented recurrence or date of death from any cause, whichever came first, assessed up to 36 months

• 3y-OS rate

  From enrollment until the date of death from any cause, assessed up to 36 months

Study Arms (1)

Experimental: Envafolimab+Chemotherapy Group（EC Group）

EXPERIMENTAL

Envafolimab: 150mg, subcutaneous injection, administered on days 1, 8, and 15, treated for 3 weeks, followed by a 1-week rest period; Albumin bound paclitaxel: administered on days 1, 8, and 15, 100 mg/m2, IV , treated for 3 weeks, followed by a 1-week rest period; Carboplatin: administered on days 1, AUC 5, treated for 3 weeks, followed by a 1-week rest period. All patients will receive treatment with Envafolimab combined with albumin bound paclitaxel and carboplatin for three weeks, followed by one week of rest and a 28 day treatment cycle, for a total of two cycles. Then, the tumor condition of the patients will be evaluated to determine whether surgical treatment is feasible.

Drug: Chemotherapy （Albumin bound paclitaxel and Carboplatin）

Interventions

Chemotherapy （Albumin bound paclitaxel and Carboplatin） DRUG

Albumin bound paclitaxel: administered on days 1, 8, and 15, 100 mg/m2, IV , treated for 3 weeks, followed by a 1-week rest period; Carboplatin: administered on days 1, AUC 5, treated for 3 weeks, followed by a 1-week rest period.

Also known as: Albumin bound paclitaxel and Carboplatin

Experimental: Envafolimab+Chemotherapy Group（EC Group）

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• The subjects voluntarily joined this study, were able to sign the informed consent form, and had good compliance;
• Age ≥ 18 years old (when signing the informed consent form);
• ECOG score 0-1 points;
• Diagnosed with operable esophageal squamous cell carcinoma through pathological diagnosis (pathological tissue/cytology) and imaging;
• The clinical TNM staging is T2-4aNxM0
• Patients assessed to require routine neoadjuvant therapy;
• Have not received immunotherapy, chemotherapy, targeted therapy, or radiotherapy in the past;
• Expected survival ≥ 12 weeks

You may not qualify if:

• The subjects have any active autoimmune diseases or a history of autoimmune diseases (such as but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, pituitary inflammation, vasculitis, nephritis, thyroid dysfunction (hyperthyroidism/hypothyroidism), and the use of drugs cannot maintain thyroid function within the normal range, or patients who have undergone thyroid surgery and require long-term replacement therapy with thyroid hormone and other drugs after surgery); Subjects with vitiligo or complete remission of childhood asthma who do not require any intervention in adulthood may be included; Asthma in which subjects require bronchodilators for medical intervention cannot be included
• The subject has previous or concurrent malignant tumors;
• Patients who have received systemic anti-tumor therapy in the past;
• Individuals who have undergone significant surgical treatment, open biopsy, or significant traumatic injury within 28 days prior to the start of treatment; Or there may be wounds or fractures that have not been cured for a long time;
• There is a risk of bleeding, coagulation dysfunction, or currently undergoing thrombolytic therapy; Or have experienced esophageal or gastric variceal rupture bleeding in the past 6 months;
• It is known that the subject has a history of allergies to large molecule protein preparations or drug ingredients used;
• Subjects with any severe and/or uncontrolled illnesses
• Ascites or pleural effusion with clinical symptoms cannot be controlled with medication and require therapeutic puncture or drainage;
• The subject is known to have a history of substance abuse, alcoholism, or drug use;
• The researchers believe that participants should be excluded from this study, for example, if the researchers determine that there are other factors that may cause the study to be terminated midway

Sponsors & Collaborators

• Shanghai Zhongshan Hospital: lead
• Jiangsu Simcere Pharmaceutical Co., Ltd.: collaborator

Study Sites (1)

Shanghai Zhongshan Hospital

Shanghai, Shanghai Municipality, 200032, China

RECRUITING

MeSH Terms

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

Carboplatin; Albumin-Bound Paclitaxel

Condition Hierarchy (Ancestors)

Carcinoma, Squamous Cell; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Squamous Cell; Esophageal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Head and Neck Neoplasms; Digestive System Diseases; Esophageal Diseases; Gastrointestinal Diseases

Intervention Hierarchy (Ancestors)

Coordination Complexes; Organic Chemicals; Paclitaxel; Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Diterpenes; Terpenes; Albumins; Proteins; Amino Acids, Peptides, and Proteins

Central Study Contacts

Di Ge, MD

CONTACT

86-18202188606; gedi@zs-hospital.sh.cn

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Ge Di., MD

Study Record Dates

• First Submitted: November 25, 2025
• First Posted: December 5, 2025
• Study Start: December 1, 2023
• Primary Completion (Estimated): June 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: December 5, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)